Clinical trial

Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.

NCT01884675

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2013-09-01

PhasePHASE3

Study timeline

Study start (unknown)2013-09-01Date precision: month

Registry last updated2017-03-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hypertensionunresolved

Interventions

Ambrisentan 5 mgDRUG · verified · RxNorm: ambrisentan 5 MG

PlaceboDRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

SeoulSouth Korea3 BeijingChina3 TokyoJapan2 BostonMassachusetts, United States1 DallasTexas, United States1 MadridSpain1 BarcelonaSpain1 LondonUnited Kingdom1 PragueCzechia1 ShanghaiChina1 SevilleSpain1 EdmontonAlberta, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01884675 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.